Finance

Lists
Q3 2026 earnings • released • EPS miss -27.19% • Revenue miss -83.85%
See results
CTMX:NASDAQ
CytomX Therapeutics Inc
$1.98
-9.59%
(-0.21) 1D
$1.98
0.00% (0.00)
Pre-market
Closed: Nov 9, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CTMX...
Open
$2.24
High
$2.28
Low
$1.95
Mkt. cap
431.44M
Avg. vol.
3.76M
Volume
584.49K
52-wk high
$8.20
52-wk low
$1.95
EPS
-$0.46
Beta
2.23
Shares outstanding
218.00M
No. of employees
69
Open
$2.24
High
$2.28
Low
$1.95
Mkt. cap
431.44M
Avg. vol.
3.76M
Volume
584.49K
52-wk high
$8.20
52-wk low
$1.95
EPS
-$0.46
Beta
2.23
Shares outstanding
218.00M
No. of employees
69
News stories
From web sources and news partners
About CytomX Therapeutics Inc
CEO-
Employees69
Founded2008
HeadquartersSouth San Francisco, California, United States
SectorHealth Care
IndustryBiotechnology
Websitecytomx.com
Analyst ratings
Based on 6 analysts giving stock ratings to CTMX in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for CTMX in the last 3 months.
Highest
Current $1.98
$16.00 (+708.08%)
Average
$12.83 (+547.98%)
Lowest
$11.00 (+455.56%)
Analyst
Recommendation
Action
Price target
Projected
Date
Olivia Brayer
Cantor Fitzgerald
Buy
Maintained
$12.00
+506.1%
11/05/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$12.00
+506.1%
11/06/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$14.00
+607.1%
11/05/2026
Robert Driscoll
Wedbush
Buy
Maintained
$12.00
+506.1%
11/06/2026
Etzer Darout
Barclays
Buy
Maintained
$16.00
+708.1%
11/06/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
$11.00
+455.6%
08/17/2026
Kalpit Patel
Wolfe Research
Buy
Initiated
$6.00
+203%
05/19/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$12.00
+506.1%
05/13/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Maintained
$11.00
+455.6%
05/11/2026
Roger Song
Jefferies
Buy
Reiterated
$16.00
+708.1%
03/18/2026
Last report
Nov 5, 2026
Fiscal period
Q3 2026
-$0.09 / -$0.07
-27.19%miss
Revenue / Est. (USD)
1.69M / 10.45M
-83.85%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
663.00K
10.26M
1.42M
1.69M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
19.54M
19.24M
17.60M
16.48M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.26M
10.69M
7.60M
8.71M
Operating expense
25.80M
29.93M
25.20M
25.19M
Total operating expenses
25.80M
29.93M
25.20M
25.19M
Operating income
-25.13M
-19.67M
-23.78M
-23.50M
Other non operating income
-
-
-
-
EBT including unusual items
-26.46M
-18.19M
-20.61M
-19.94M
EBT excluding unusual items
-23.66M
-18.19M
-20.61M
-19.94M
Income tax expense
54.00K
59.00K
60.00K
61.00K
Effective tax rate
-0.20%
-0.32%
-0.29%
-0.31%
Other operating expenses
-
-
-
-
Net income
-26.51M
-18.25M
-20.67M
-20.00M
Net profit margin
-3,998.49%
-177.89%
-1,457.40%
-1,184.72%
Earnings per share
-0.22
-0.10
-0.09
-0.09
Interest and investment income
1.48M
1.49M
3.16M
3.27M
Interest expense
-
-
-
-
Net interest expenses
1.48M
1.49M
3.16M
3.27M
Depreciation and amortization charges
-
-
-
-
EBITDA
-24.62M
-19.42M
-23.73M
-23.09M
Gain or loss from assets sale
-
-
-
-293.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps